Julian Harrison
Stock Analyst at BTIG
(3.66)
# 1,171
Out of 4,583 analysts
32
Total ratings
51.85%
Success rate
8.14%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.87 | +208.01% | 2 | Sep 10, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $46 → $56 | $21.06 | +165.91% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $9.91 | +152.27% | 3 | Aug 20, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $41 → $51 | $44.77 | +13.92% | 2 | Jul 24, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Neutral | n/a | $1.91 | - | 4 | Jun 17, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $43 | $11.37 | +278.19% | 1 | May 20, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $32 → $40 | $28.96 | +38.12% | 2 | May 10, 2024 | |
| TBPH Theravance Biopharma | Initiates: Buy | $21 | $8.27 | +153.93% | 1 | Apr 12, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $50 | $5.93 | +743.17% | 3 | Mar 27, 2024 | |
| ANAB AnaptysBio | Initiates: Buy | $55 | $36.57 | +50.40% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.17 | - | 3 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $53.34 | -19.39% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $1.35 | +196.30% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $3.52 | +4,161.36% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $53.11 | -32.22% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $55.71 | +88.48% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $342.59 | - | 2 | Feb 11, 2022 |
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.87
Upside: +208.01%
Viridian Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $46 → $56
Current: $21.06
Upside: +165.91%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $9.91
Upside: +152.27%
Protagonist Therapeutics
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $44.77
Upside: +13.92%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
ABIVAX Société Anonyme
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $11.37
Upside: +278.19%
Spyre Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $28.96
Upside: +38.12%
Theravance Biopharma
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $8.27
Upside: +153.93%
Outlook Therapeutics
Mar 27, 2024
Upgrades: Buy
Price Target: $50
Current: $5.93
Upside: +743.17%
AnaptysBio
Feb 26, 2024
Initiates: Buy
Price Target: $55
Current: $36.57
Upside: +50.40%
Jan 11, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $53.34
Upside: -19.39%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.35
Upside: +196.30%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $3.52
Upside: +4,161.36%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $53.11
Upside: -32.22%
Dec 13, 2022
Maintains: Buy
Price Target: $95 → $105
Current: $55.71
Upside: +88.48%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $342.59
Upside: -